Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. company information, Employees & Contact Information

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes. AXPAXLI™ (also known as OTX-TKI), an investigational axitinib hydrogel administered by intravitreal injection, is Ocular’s leading investigational candidate for retinal disease, based on its proprietary ELUTYX™ technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and has potential applications across other retinal diseases such as non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME).

Company Details

Employees
308
Founded
-
Address
15 Crosby Drive, Bedford,ma 01730,united States
Phone
(781)357-4000
Email
in****@****utx.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
ocutx.com
HQ
Bedford, MA
Looking for a particular Ocular Therapeutix, Inc. employee's phone or email?

Ocular Therapeutix, Inc. Questions

News

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock - Yahoo Finance

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock Yahoo Finance

Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025 - GlobeNewswire

Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025 GlobeNewswire

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewswire

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences GlobeNewswire

Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021 - FinancialContent

Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021 FinancialContent

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease - Business Wire

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease Business Wire

Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewswire

Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025 GlobeNewswire

Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases - Business Wire

Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases Business Wire

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ - GlobeNewswire

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ GlobeNewswire

Ocular Therapeutix™ and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia - Business Wire

Ocular Therapeutix™ and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia Business Wire

Top Ocular Therapeutix, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant